Filtered By:
Cancer: Brain Cancers
Management: Venture Capital

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Korean JLK Inspection launches AI-powered imaging diag system
Korean JLK Inspection said yesterday that it launched its AIHub artificial intelligence-powered medical image diagnostics platform. The newly launched AIHub system is designed to analyze images from a number of different imaging modalities, including magnetic resonance imaging, computed tomography, X-ray and mammography, the Seoul-based company said. JLK Inspection claims the system can detect and monitor for more than 30 medical conditions in 14 regions of the body. The company added that the system is focused on brain diseases and conditions including ischemic stroke, hemorrhagic stroke, brain aneurysm and Alzheimer̵...
Source: Mass Device - December 27, 2018 Category: Medical Devices Authors: Fink Densford Tags: Diagnostics Imaging Software / IT jlkinspection Source Type: news

Neuroscience is the Next Oncology
by Michael D. Ehlers, MD, PhD Dr. Ehlers is with Biogen in Cambridge, Massachusetts. Innov Clin Neurosci. 2018;15(3–4):15–16 Funding: No funding was received for the preparation of this article. Disclosures: Dr. Ehlers is an employee and shareholder at Biogen Inc. in Cambridge, Massachusetts. Prominent and expensive failures in Alzheimer’s disease therapies have led to a contagious belief system in some parts of the biopharma industry that neuroscience is just too hard, too risky, and too uncertain. But, might this belief system itself be a residual bias of the past? Close inspection reveals all the signs of a coming...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Commentary Current Issue Source Type: research

UCLA helps many to live long and prosper
In Westwood, more than 100 faculty experts from 25 departments have embarked on anall-encompassing push to cut the health and economic impacts of depression in half by the year 2050. The mammoth undertaking will rely on platforms developed by the new Institute for Precision Health, which will harness the power of big data and genomics to move toward individually tailored treatments and health-promotion strategies.On the same 419 acres of land, researchers across the spectrum, from the laboratory bench to the patient bedside, are ushering in a potentially game-changing approach to turning the body ’s immune defenses again...
Source: UCLA Newsroom: Health Sciences - November 9, 2017 Category: Universities & Medical Training Source Type: news